Sirtris Pharmaceuticals CEO to Speak at Technology Review’s Emerging Technologies Conference at MIT on September 28th, 2006

CAMBRIDGE, Mass.--Sept. 26, 2006--Sirtris Pharmaceuticals, the leading sirtuin therapeutics company, announced today that Sirtris CEO, Christoph Westphal, M.D., Ph.D. will be speaking on the Anti-Aging Research panel at the Technology Review’s Emerging Technologies Conference at MIT at 1:45 EDT on Thursday, September 28th, 2006.

New findings on diseases of aging are included at this year’s Emerging Technologies Conference at MIT, as an example of technological innovation to improve lives, create opportunities, and fuel economic growth. Dr. Westphal will participate in the Anti-Aging Research panel which will discuss recent discoveries about mechanisms of human aging and the potential to impact aging processes and diseases. Dr. Westphal will describe the scientific breakthrough of sirtuins, a recently-discovered new class of enzymes, and how Sirtris Pharmaceuticals is pioneering the development of novel drugs targeted to modulate sirtuins for the treatment of diseases of aging, such as diabetes.

Phillip A. Sharp, Ph.D., MIT Institute professor, Nobel laureate and Sirtris Scientific Advisory Board member will also present at this conference.

About Sirtuins

Sirtuins are a recently discovered family of enzymes that promote normal cellular function. In particular, sirtuins improve the function of mitochondria which generate energy in cells. When organisms face adversity, sirtuins are activated as part of a natural process that maintains healthy function.

Therefore, sirtuins are attractive drug targets which may be therapeutically beneficial for diseases in which mitochondria are dysfunctional, often observed in diseases of aging. These diseases include metabolic diseases such as Type 2 Diabetes, neurological diseases, and other mitochondrial disorders. Sirtuin therapeutics offer the potential for a novel class of drugs that can treat significant diseases of aging in a new way.

About Sirtris Pharmaceuticals

Sirtris Pharmaceuticals is a biopharmaceutical company developing novel therapeutics that modulate sirtuins. Sirtris has the dominant sirtuin intellectual property estate and know-how with a comprehensive suite of reagents, proprietary assays, transgenic animal models, and biomarkers. Sirtris is building a robust pipeline of therapeutics for diseases of aging in the areas of metabolic and neurological diseases.

Sirtris Pharmaceuticals was founded in 2004 by Rich Aldrich, Richard Pops, Paul Schimmel, David Sinclair and Christoph Westphal and has raised a total of $82 million since inception from investors

including: Bessemer Venture Partners, Cardinal Partners, Cargill Ventures, Genzyme Ventures, Novartis Bioventures Fund, Polaris Venture Partners, QVT Fund LP, Skyline Ventures, The Wellcome Trust, Three Arch Partners, and TVM Capital. The company’s headquarters are in Cambridge, Massachusetts. For additional information, please visit http://www.sirtrispharma.com.